Affiliation:
1. University of Otago
2. Black Dog Institute, University of New South Wales
3. Singapore General Hospital
4. China Medical University Hospital.
5. Kings College London
6. Douglas Pharmaceuticals Ltd
Abstract
Abstract
Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerability of racemic ketamine may be improved if given orally, as an extended release tablet (R-107), compared with other routes of administration. In this phase 2 multicentre clinical trial, adult patients with TRD and Montgomery-Asberg Depression Rating Scale (MADRS) scores >20 received open label R-107 tablets 120mg/day for 5 days and were assessed on Day 8 (enrichment phase). On Day 8, responders (MADRS scores <12 and reduction >50%) were randomized on a 1:1:1:1:1 basis to receive double-blind R-107 doses of 30, 60, 120, or 180mg, or placebo, twice weekly for a further 12 weeks. Non-responders on Day 8 exited the study. The primary endpoint was least square mean change in MADRS for each active treatment compared with placebo at 13 weeks, starting with the 180mg dose, using a fixed sequence step-down closed test procedure. Between August 2016 and April 2020, 329 individuals were screened for eligibility, 231 entered the open label enrichment phase (Days 1-8), and 168 responders were randomized to double-blind treatment. The primary objective was met; the least square mean difference of MADRS score for the 180mg tablet group and placebo was -6.1 (95% CI 1.0-11.16, p=0·019) at 13 weeks. Relapse rates during double-blind treatment showed a dose-response, from 70.6% for placebo, to 42.9% for 180mg. Tolerability was excellent, with no changes in blood pressure, minimal reports of sedation, and minimal dissociation. The most common adverse events were headache, dizziness and anxiety. During the randomised phase of the study most patient dosing occurred at home. R-107 tablets were effective, safe and well-tolerated in a patient population with TRD, enriched for initial response to R-107 tablets. Clinical Trial Registration ACTRN12618001042235.
Publisher
Research Square Platform LLC
Reference27 articles.
1. Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C. Jr, Vazquez, G., Loo, C. Ketamine for the treatment of major depression: a systematic review and meta-analysis. EClinicalMedicine., 62, 102127 (2023).
2. Esketamine for treatment-resistant depression—first FDA-approved antidepressant in a new class;Kim J;New Engl J Med,2019
3. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation;McIntyre RS;Am J Psychiatry,2021
4. Hydroxynorketamines: pharmacology and potential therapeutic applications;Highland JN;Pharmacol Rev.,2021
5. (R, S)-Ketamine metabolites (R, S)-norketamine and (2S, 6S)-hydroxynorketamine increase the mammalian target of rapamycin function;Paul RK;Anesthesiology,2014
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献